IntraLinks Announces Partnership With SAFE-BioPharma; Will Provide Digital Identity Capabilities With its Life Sciences Solutions

IntraLinks will Help to Meet the Pharmaceutical Industry's Objective to Move Towards Completely Paperless Clinical Trials

NEW YORK, May 12, 2010 - IntraLinks, the leading provider of critical information exchange
solutions, today announced a partnership with SAFE-BioPharma, the non-profit
association that created and manages the SAFE-BioPharma(R) digital identity
and signature standard for the pharmaceutical and healthcare industries.
IntraLinks users, which include the top 10 pharmaceutical, biotechnology and
contract research organizations (CROs) worldwide, will now be able to use the
SAFE-BioPharma digital identity for signing documents. They can increase
clinical trial efficiency by signing paperwork with a SAFE credential that
provides additional security and speed, eliminating printing of hard copy
casebooks and other documents.

IntraLinks provides automated and secure document sharing solutions for
the life sciences industry. Its' SaaS-based platform already helps
pharmaceutical and clinical and safety teams achieve greater efficiencies,
improve regulatory compliance and reduce risk but providing an alternative to
the "wet" signature will help to take this to the next level. Users will have
the opportunity to securely upload and use their SAFE-BioPharma digital
identities on the IntraLinks(R) platform, ensuring that their credentials are
available anytime and anywhere via the Web. IntraLinks is also enabling
documents signed with SAFE-BioPharma signatures to be stored and shared on
its existing platform.

"Incorporating SAFE-BioPharma's digital identity and signature standard
into IntraLinks' platform is very significant for our clients and the
community who rely on IntraLinks to manage their clinical trial communication
and document exchange," said Alison Shurell, VP, life sciences product
marketing, IntraLinks. "In addition to already being able to securely upload,
receive, review and distribute documents on IntraLinks, sponsors, CROs and
investigators will soon be able to eliminate the need to print out or
physically store the numerous documents that require signatures during a
clinical trial. It was an easy choice for us to partner with SAFE-BioPharma
because its digital signature standard is recognized in the life sciences
industry for providing a secure, enforceable, and regulatory-compliant way to
verify identities and apply digital signatures in electronic transactions."

"Our mission is to facilitate the transformation of the pharmaceutical
and healthcare communities to a fully electronic business environment by
2015," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma. "
SAFE-BioPharma members welcome the incorporation of the community's digital
identity and signature standard into the IntraLinks platform. This new
capability will help life sciences professionals further simplify and manage
compliance and security within a seamless paperless environment."

In addition to incorporating the digital signature into its platform,
IntraLinks has joined the SAFE-BioPharma vendor partner community. Members
already include companies such as Microsoft, IBM, Adobe and Citigroup.

About IntraLinks

IntraLinks is a leading global provider of Software-as-a-Service
solutions for securely managing content, exchanging critical business
information and collaborating within and among organizations. More than
1,000,000 professionals in industries including financial services,
pharmaceutical, biotechnology, consumer, energy, industrial, legal,
insurance, real estate and technology, as well as government agencies, have
utilized IntraLinks' easy-to-use, cloud-based solutions. IntraLinks users can
accelerate information-intensive business processes and workflows, meet
regulatory and risk management requirements and collaborate with customers,
partners and counterparties in a secure, auditable and compliant manner.
IntraLinks counts 800 of the Fortune 1000 as users. For more information,
visit www.intralinks.com or blog.intralinks.com. You can also
follow IntraLinks on Twitter at twitter.com/intralinks and Facebook at
www.facebook.com/IntraLinks.

About SAFE-BioPharma Association (www.safe-biopharma.org)

SAFE-BioPharma Association is the non-profit association that created and
manages the SAFE-BioPharma(R) digital identity and signature standard for the
pharmaceutical and healthcare industries. It provides users with a secure,
enforceable, and regulatory compliant way to verify identities of parties
involved in electronic transactions and to apply digital signatures to
electronic documents.

The Association's members include:

    - Abbott (NYSE: ABT)
    - Amarin Corp. (NASDAQ: AMRN),
    - Amgen (NASDAQ: AMGN)
    - AstraZeneca (NYSE: AZN)
    - Bristol-Myers Squibb (NYSE:BMY)
    - GlaxoSmithKline (NYSE: GSK)
    - Johnson & Johnson (NYSE: JNJ)
    - Eli Lilly (NYSE: LLY)
    - McDougall Scientific
    - Merck (NYSE:MRK)
    - MWB Consulting Limited
    - National Notary Association
    - Oxford Outcomes
    - Pfizer (NYSE: PFE)
    - Premier Inc.
    - Roche
    - Sanofi-Aventis (NYSE:SNY).
    - SNAP Diagnostics

SAFE-BioPharma(R) is a registered trademark of SAFE-BioPharma
Association. Any use of this trademark requires approval from SAFE-BioPharma
Association.

Contact Radley Moss, rmoss@intralinks.com, +1-212-543-7717

Contact Radley Moss, rmoss at intralinks.com, +1-212-543-7717